Effects of fluticasone furoate nasal spray on local eosinophil chemokine production

What is it about?

We investigated the relationship between the local production of RANTES and eotaxin-2, two eosinophil hemoattractants in chronically inflamed sinonasal mucosa, and eosinophilia in the nasal mucosa of patients with perennial allergic rhinitis and CRSwNP, before and after intranasal fluticasone furoate treatment. We, also assessed the effects of fluticasone furoate on their nasal symptoms and endoscopic findings. Fluticasone furoate is well known intranasal corticosteroid medication for the therapy of allergic rhinitis. However, to our knowledge, only one article concerning the effects of fluticasone furoate on clinical and immunological outcomes for patients with nasal polyposis has been previously published. Objectives. ‘Regulated on Activation Normal T Cell Expressed and Secreted’ (RANTES) and eotaxin-2 have been postulated to be responsible for eosinophilia in chronically inflamed nasal mucosa. This study evaluated mucosal production of RANTES and eotaxin-2 in patients with perennial allergic rhinitis (PAR), non-allergic and allergic form of chronic rhinosinusitis with nasal polyps (CRSwNP), before and after nasal corticosteroid treatment. Methods. Twenty patients with PAR, 20 non-allergic and 20 allergic CRSwNP patients and 20 healthy controls were included. RANTES and eotaxin-2 levels were measured in nasal secretion samples. The patients with chronic inflammation were treated with fluticasone furoate nasal spray for two weeks. Cytological examination and measurement of RANTES and eotaxin-2 in nasal fluid were performed before and after the treatment. Results. The levels of RANTES were higher in patients with PAR (p<0.05), non-allergic (p<0.01) and allergic CRSwNP patients (p<0.001) compared to controls. Eotaxin-2 levels were higher in all three inflammation groups comparing to healthy subjects (p<0.001). After the treatment, we found a significant decrease of RANTES and eotaxin-2 concentrations (p<0.001) in all three groups of patients. Conclusion. The levels of RANTES and eotaxin-2 in nasal fluid could be reliable markers for assessing corticosteroid administration outcomes. You can find full text article at link: http://journals.sagepub.com/eprint/XqxqZtcCtKhi4nKupCqX/full

Featured Image

Why is it important?

Fluticasone furoate is well known intranasal corticosteroid medication for the therapy of allergic rhinitis. However, to our knowledge, only one article concerning the effects of fluticasone furoate on clinical and immunological outcomes for patients with nasal polyposis has been previously published.

Perspectives